|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy显示文摘Hepatitis due to hepatitis B virus(HBV) reactivation can be severe and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving cancer chemotherapy, especially rituximabcontaining therapy for hematological malignancies and those receiving stem cell transplantation. All patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBs Ag) and antibody to hepatitis B core antigen(antiHBc). Patients found to be positive for HBs Ag should be given prophylactic antiviral therapy to prevent HBV reactivation. For patients with resolved HBV infection, no standard strategy has yet been established to prevent HBV reactivation. There are usually two options. One is pre-emptive therapy guided by serial HBV DNA monitoring, whereby antiviral therapy is given as soon as HBV DNA becomes detectable. However, there is little evidence regarding the optimal interval and period of monitoring. An alternative approach is prophylactic antiviral therapy, especially for patients receiving highrisk therapy such as rituximab, newer generation of anti-CD20 monoclonal antibody, obinutuzumab or hematopoietic stem cell transplantation. This strategy may effectively prevent HBV reactivation and avoid the inconvenience of repeated HBV DNA monitoring. Entecavir or tenofovir are preferred over lamivudine as prophylactic therapy. Although there is no well-defined guideline on the optimal duration of prophylactic therapy, there is growing evidence to recommend continuing prophylactic antiviral therapy for at least 12 mo after cessation of chemotherapy, and even longer for those who receive rituximab or who had high serum HBV DNA levels before the start of immunosuppressive therapy. Many novel agents have recently become available for the treatment of hematological malignancies, and these agents may be associated with HBV reactivation. Although there is currently limited evidence to guide the optimal preventive measures, we recommend antiviral prophylaxis in HBs Ag-positive patients receiving novel treatments, especially the Bruton tyrosine kinase inhibitors and the phosphatidylinositol 3-kinase inhibitors, which are B-cell receptor signaling modulators and reduce proliferation of malignant B-cells. Further studies are needed to clarify the risk of HBV reactivation with these agents and the best prophylactic strategy in the era of targeted therapy for hematological malignancies. | Man Fai Law Rita Ho Carmen KM Cheung Lydia HP Tam Karen Ma Kent CY So Bonaventure Ip Jacqueline So Jennifer Lai Joyce Ng Tommy HC Tam | 2016 | World Journal of Gastroenterology2016，22，28： | 10 |
| 2 | Intermuscular variation in tenderness: Association with the ubiquitous and muscle-specific calpains 显示文摘 | Ilian MA Morton JD Kent MP | 2001 | J Anita Sci2001，79，： | 1 |
| 3 | Central and peripheral renin-angiotensin systems in ouabain-induced hypertension显示文摘 | Cheung WJ Kent MA E1-Shahat E | | 0，，： | 1 |
| 4 | Placement of endosseous implants into tooth extractions sites显示文摘 | Block MA Kent JN | | 0，，09： | 1 |
| 5 | Revisiting Colostomy Irrigation:A Viable Option for Persons With Permanent Descending and Sigmoid Colostomies显示文摘 | Kent DJ Long MA Bauer C | 2015 | Journal of Wound Ostomy & Continence Nursing2015，42，2： | 1 |
| 6 | FOSL1 is integral to establishing the maternal-fetal interface显示文摘 | Kent LN Rumi MA Kubota K | 2011 | Mol Cell Biol2011，31，23： | 1 |
| 7 | Incidence of retinopathy of pre- maturity requiring treatment in infants born greater than 30 weeks gesta- tion and with a birth weight greater than 1250 g from 1998 to 2002 : a regional study 显示文摘 | Ahmed MA Duncan M Kent A | 2006 | J Paediatr Child Health2006，42，6： | 1 |
| 8 | Interferon Alfacon-1 and Ribavirin Versus Interferon α-2b and Ribavirin in the Treatment of Chronic Hepatitis C显示文摘 | Maria H. Sjogren MD Robert Sjogren MD Kent Holtzmuller MD Bradley Winston MD Betty Butterfield MD Stanley Drake MD Amber Watts MA Robin Howard MA Milton Smith MD | 2005 | Digestive Diseases and Sciences2005，，4： | 1 |
| 9 | Aspirin use and post-operative bleeding from dental extraction显示文摘 | Brennan MT Valerin MA Kent ML | 2008 | J Dent Res2008，87，8： | 1 |
| 10 | Invariant natural killer T cell deficiency and functional impairment in sleep apnea:links to cancer comorbidity显示文摘 | GAOATSWE G KENT BD CORRIGAN MA | 2015 | Sleep2015，38，10： | 1 |
| 11 | Axillary Reverse Mapping (ARM): A New Concept to Identify and Enhance Lymphatic Preservation显示文摘 | Margaret Thompson MD Soheila Korourian MD Ronda Henry-Tillman MD Laura Adkins MAP Sheilah Mumford MA Kent C. Westbrook MD V Suzanne Klimberg MD | 2007 | Annals of Surgical Oncology2007，，6： | 1 |
| 12 | Central and peripheral renin-an- giotensin systems in ouabain-induced hypertension 显示文摘 | Cheung W J Kent MA E 1-Shahat E | 2006 | American Journal of Physiology2006，19，23： | 1 |
| 13 | Lymph node dissection during cytoreductive nephrectomy: a retrospective analysis显示文摘 | FEUERSTEIN MA KENT M BERNSTEIN M | 2014 | Int J Urol2014，21，9： | 1 |
| 14 | Intermuscular variation in tenderness: Association with the ubiquitous and muscle-specific calpains显示文摘 | Ilian MA Morton JD Kent MP | 2001 | J Anim Sci2001，79，： | 1 |
| 15 | Prospective Identification of Risk Factors for Wound Infection After Lower Extremity Oncologic Surgery显示文摘 | Carol D. Morris MD MS Kent Sepkowitz MD Claudette Fonshell RN Neil Margetson MA Janet Eagan RN MPH Jeremy Miransky PhD Patrick J. Boland MD John Healey MD | 2003 | Annals of Surgical Oncology2003，，7： | 1 |
| 16 | Intermuscular variation in tenderness:association with the ubiquitous and muscle-specific calpains显示文摘 | Morton JD Kent MP | 2001 | AnimSci2001，79，1： | 1 |
| 17 | Inci- dence of retinopathy of prematurity requiring treatment in infants born greater than 30 week's gestation and with a birth weight greater than 1250g from 1998 to 2002 a regional study 显示文摘 | Ahmed MA Duncan M Kent A | 2006 | J Paediatr Child Health2006，42，6： | 1 |
| 18 | Vaginal rejuvenation: an in-depth look at the history and technical procedure显示文摘 | Kent D Pelosi MA Ⅲ | 2012 | AJCS2012，29，2： | 1 |
| 19 | Protection against Chemical Warfare Agents and Biological Threats Using Metal−Organic Frameworks as Active Layers显示文摘The SARS-CoV-2 pandemic outbreak and the unfortunate misuse of toxic chemical warfare agents(CWAs)highlight the importance of developing functional materials to protect against these chemical and pathogen threats.Metal−organic frameworks(MOFs),which comprise a tunable class of crystalline porous materials built from inorganic nodes and organic linkers,have emerged as a class of heterogeneous catalysts capable of rapid detoxification of multiple classes of these harmful chemical or biological hazards.In particular,zirconium-based MOFs(Zr-MOFs)feature Lewis acidic nodes that serve as active sites for a wide range of catalytic reactions,including the hydrolysis of organophosphorus nerve agents within seconds in basic aqueous solutions.In addition,postsynthetic modification of Zr-MOFs enables the release of active species capable of reacting with and deactivating harmful pathogens.Despite this impressive performance,utilizing Zr-MOFs in powder form is not practical for application in masks or protective uniforms.To address this challenge,our team sought to develop MOF/fiber composite systems that could be adapted for use under realistic operating conditions to protect civilians,military personnel,and first responders from harmful pathogens and chemical warfare agents.Over the last several years,our group has designed and fabricated reactive and biocidal MOF/fiber composites that effectively capture and deactivate these toxic species.In this Account,we describe the evolution of these porous and reactive MOF/fiber composites and focus on key design challenges and considerations.First,we devised a scalable method for the integration of Zr-MOFs onto textile substrates using aqueous precursor solutions and without using pretreated textiles,highlighting the potential scalability of this method.Moving beyond standard textiles,we also developed a microbial synthesis strategy to prepare hierarchically porous MOF/bacterial cellulose nanofiber composite sponges that can both capture and detoxify nerve agents when exposed to contaminated gas flows.The mass loading of the MOF in the nanofibrous composite sponge is up to 90%,affording higher work capacities compared to those of textile-fiber-based composites with relatively lower MOF loadings.Next,we demonstrated that heterogeneous polymeric bases are suitable replacements for volatile liquid bases typically used in solution-phase reactions,and we showed that these composite systems are capable of effectively hydrolyzing nerve agents in the solid state by using only water that is present as humidity.Moreover,incorporating a reactive dye precursor into the composite affords a dual function sensing and detoxifying material that changes color from white to orange upon reaction with the byproduct following nerve agent hydrolysis,demonstrating the versatility of this platform for use in decontamination applications.We then created chlorine-loaded MOF/fiber composites that act as biocidal and reactive textiles that are capable of not only detoxifying sulfur-mustard-based chemical warfare agents and simulants but also deactivating both bacteria and the SARS-CoV-2 virus within minutes of exposure.Finally,we synthesized a mixed-metal Ti/Zr-MOF coating on cotton fibers to afford a photoactive biocidal cloth that shows fast and broad-spectrum biocidal performance against viruses and Gram-positive and Gram-negative bacteria under visible light irradiation.Given the tunable,multifunctional nature of these MOF/fiber composites,we believe that this Account will offer new insights for the rational design and preparation of functional MOF/fiber composites and pave the way toward the development of next-generation reactive and protective textiles. | Kaikai Ma Yuk Ha Cheung Kent O.Kirlikovali Xiaoliang Wang Timur Islamoglu John H.Xin Omar K.Farha | 2023 | Accounts of Materials Research2023，4，2： | 1 |
| 20 | Interferon Alfacon-1 and Ribavirin Versus Interferon α-2b and Ribavirin in the Treatment of Chronic Hepatitis C显示文摘 | Maria H. Sjogren MD Robert Sjogren MD Kent Holtzmuller MD Bradley Winston MD Betty Butterfield MD Stanley Drake MD Amber Watts MA Robin Howard MA Milton Smith MD | 2005 | Digestive Diseases and Sciences2005，，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员